How to Navigate Global Regulatory Submissions Without a Full RA Team
Global regulatory submissions are complex at the best of times. Running them without a full regulatory affairs team is the reality for a significant number of pharmaceutical companies. This is particularly true for those in growth stages, those with lean commercial structures, and those entering new markets for the first time.
The absence of a dedicated in-house RA function does not have to mean delayed filings, inconsistent dossiers, or misjudged agency strategy. It does mean the approach has to be structured, deliberate, and supported by the right expertise at the right time.
This post sets out how to navigate multi-market regulatory submissions without a full RA team. What to prioritise, where the gaps typically appear, and how to build a submission programme that holds up under agency scrutiny.
The core challenge:
• Multi-market submissions require simultaneous management of different regulatory requirements, dossier formats, agency expectations, and timelines
• Without a dedicated RA team, this coordination burden typically falls on people who are already operating at capacity
• The risk is not just delay. Inconsistent or incomplete submissions can trigger agency questions, clock stops, and reputational damage with regulators
Understand the regulatory landscape before you file
The most common mistake companies make when entering new markets is treating global submissions as a documentation exercise rather than a strategy exercise. Filing the wrong dossier format, misjudging the agency's scientific expectations, or underestimating local requirements creates problems that are expensive and time-consuming to fix.
Before any submission programme begins, there are three questions that need clear answers.
1. Which markets are priority and in what sequence? Regulatory pathways and approval timelines vary significantly. The ICH Common Technical Document (CTD) structure is accepted by most major agencies, but the requirements layered on top differ, sometimes substantially. Markets should be sequenced based on strategic importance, pathway feasibility, and data readiness.
2. What is the regulatory classification of the product in each jurisdiction? Classification affects pathway, timeline, and the data package required. A product classified as a new molecular entity in one jurisdiction may be eligible for a well-established use pathway in another. Getting this wrong early creates structural problems throughout the programme.
3. What are the specific agency expectations for this product type? Agency guidance documents, precedent decisions, and pre-submission interactions all inform what a robust dossier looks like. Submitting without this intelligence is a significant risk.
Key regulatory jurisdictions and their primary submission formats:
• EMA (EU): CTD format via centralised, mutual recognition, or decentralised procedure
• MHRA (UK): Post-Brexit, the UK operates independent procedures including national, rolling review, and the International Recognition Procedure (IRP)
• FDA (US): IND, NDA, BLA, or ANDA depending on product type and development stage
• Health Canada, TGA (Australia), PMDA (Japan), ANVISA (Brazil): Each with local format requirements and procedural nuances
• Not all markets require a full CTD. Understanding local expectations for each target market is non-negotiable
Build your submission programme around the critical path
A regulatory submission is not a document. It is a programme with dependencies, decision points, and multiple workstreams running in parallel. Without a full RA team, understanding and actively managing the critical path is what separates companies that achieve timely approvals from those that repeatedly slip timelines.
The critical path for most global submissions includes the following elements.
1. Data readiness. Submissions fail or stall most frequently because the underlying data is not ready, not formatted correctly, or not accompanied by the appropriate analyses. CMC data, clinical summaries, and nonclinical packages all need to be in their final form before a high-quality dossier can be assembled.
2. Dossier compilation and quality review. The CTD is a structured document with defined module requirements. Each section needs to be complete, internally consistent, and cross-referenced correctly. Errors in compilation are a common source of agency questions and clock stops.
3. Regulatory strategy alignment. Agency scientific expectations evolve. What satisfied a regulatory question three years ago may not satisfy it today. The dossier needs to be built against current guidance rather than historical precedent.
4. Pre-submission interactions where applicable. The FDA pre-NDA meeting, the EMA scientific advice procedure, and equivalent processes with other agencies are underutilised by smaller organisations. These interactions de-risk the submission significantly. They are particularly valuable when a team is operating without deep in-house regulatory experience.
5. Post-submission management. Regulatory agencies ask questions. Clock stops happen. Responses need to be prepared quickly, accurately, and in alignment with the strategic position already established in the dossier. Without a team to manage this, response quality and timelines frequently suffer.
Working through a multi-market filing without in-house RA resource?
Learn how TDP’s Regulatory Affairs Consulting service supports global submissions →
Where gaps most commonly appear
Having worked across regulatory submissions for multiple markets, certain patterns emerge consistently when companies are operating without a full RA team.
1. Dossier inconsistency across markets. When the same clinical or CMC data is presented differently across module sections, or when the summary documents do not align with the supporting data, agencies notice. This creates unnecessary questions and delays approvals.
2. Underestimation of local requirements. Major market submissions are well-documented. Smaller or secondary markets are frequently underestimated. Local labelling requirements, translation obligations, country-specific data requirements, and registration fees can all be missed when a programme is not managed with market-specific expertise.
3. Failure to manage agency timelines actively. Regulatory procedures have defined timelines with mandatory milestones. Missing a response window or failing to request a clock stop appropriately can have significant consequences. This is a procedural skill that requires ongoing, active management throughout the submission lifecycle.
4. Reactive rather than proactive agency management. Companies that wait for agency questions before engaging strategically consistently take longer to reach approval. Proactive regulatory strategy anticipates questions, addresses known gaps in the submission, and manages agency relationships. It shortens timelines and improves outcomes.
The cost of submission gaps:
• Clock stops and additional information requests add months to approval timelines
• Inconsistent dossiers create precedent problems across other markets
• Regulatory questions on CMC or clinical data can require significant analytical resource to respond to
• Repeated delays erode confidence with agencies and can affect how future submissions are received
The outsourced model: what good looks like
For companies without a full in-house RA team, outsourcing regulatory affairs expertise is a well-established and effective model. The question is not whether to use external resource. It is how to structure it so it functions as a genuine regulatory capability rather than a documentation service.
A strong outsourced RA model delivers three things.
1. Strategic input, not just execution. The best outsourced regulatory partners provide strategic guidance on pathway selection, agency positioning, and dossier structure. They do not simply format documents. If an outsourced partner is only filling in templates, the strategic risk remains with an internal team that may not have the depth to carry it.
2. Continuity across the submission lifecycle. Regulatory submissions do not end at filing. Post-submission management, response to agency questions, and variation management all require ongoing involvement from people with full context of the dossier. The outsourced model needs to provide that continuity.
3. Market-specific expertise. Regulatory requirements differ by jurisdiction. Outsourced partners should bring genuine in-market knowledge for each jurisdiction in scope. Generic regulatory experience applied to unfamiliar markets is not sufficient.
TDP provides outsourced regulatory affairs support structured to deliver all three. Our consultants bring senior, market-specific expertise and integrate directly into client programmes as an extension of the internal team.
Practical steps to manage global submissions with a lean team
Whether using outsourced support, a hybrid model, or a genuinely small internal team, the following disciplines make the difference between a well-run submission programme and one that runs into avoidable problems.
1. Map the regulatory landscape for every target market before the programme starts. This is not optional. Assumptions about local requirements that turn out to be wrong create structural problems. Every market in scope should have a documented summary of pathway, format requirements, local obligations, and known agency sensitivities.
2. Own the critical path actively. A regulatory submission tracker covering all markets, workstreams, and dependencies should be maintained throughout the programme. Agency timelines, response windows, and internal milestones all need to be visible and actively managed.
3. Standardise the dossier architecture. Use the CTD structure as the foundation and build a common dossier that can be adapted for local markets. This reduces duplication, improves consistency, and makes multi-market filing significantly more manageable with lean resource.
4. Use pre-submission interactions strategically. For first-time submissions in a new market or with a novel product, investing in a pre-submission meeting with the agency is almost always worthwhile. The clarity gained reduces risk in the submission itself.
5. Build response capability before you need it. Agency questions require fast, accurate, and strategically aligned responses. Having a clear process for how questions are triaged, drafted, and reviewed before a clock stop arrives is essential. Scrambling to set up a response process mid-submission costs time and quality.
6. Do not underestimate post-approval obligations. Regulatory approval is the beginning of ongoing agency management. Labelling updates, variations, renewals, and periodic safety reporting all require continued regulatory resource.
Before starting a global submission programme, ensure you have clarity on:
• Priority market sequencing and the regulatory pathway for each
• Data package readiness across CMC, clinical, and nonclinical modules
• Whether pre-submission agency interactions are warranted
• How post-submission agency management will be resourced
• The RA expertise and continuity available for each market in scope
When to bring in external regulatory expertise
Companies typically bring in external RA support at one of three points: at the start of a submission programme when strategic planning is needed, during dossier compilation when specialist writing or module expertise is required, or reactively when agency questions arrive and in-house resource cannot manage the response.
The third scenario is the most expensive. Reactive engagement with a regulatory consultant mid-clock stop, working from a dossier the consultant did not build and with limited time to prepare a credible response, consistently produces worse outcomes than early engagement would have.
The optimal point to engage external RA expertise is before the submission programme starts. Strategic input at the planning stage shapes pathway selection, data package design, and dossier architecture. These are decisions that are difficult and costly to reverse once the programme is underway.
If budget or timeline means that is not possible, the next best option is to engage early in the dossier build. This gives an external consultant sufficient time to understand the programme, the data, and the agency context before filing.
Considering external RA expertise for an upcoming submission?
Summary
Navigating global regulatory submissions without a full RA team is manageable. It requires a structured approach, the right expertise available at the right points, and a programme that is actively managed from strategy through to post-approval.
The companies that achieve timely, high-quality approvals across multiple markets share common disciplines. They understand each jurisdiction before they file. They manage the critical path actively. They bring in senior regulatory expertise where it adds the most value.
Operating lean does not mean operating at a disadvantage. With the right model, a small team supported by the right outsourced expertise can run a global submission programme that matches the output of a much larger in-house function.
TDP works with pharmaceutical companies at every stage of the submission lifecycle. From strategic planning and dossier build through to post-submission management and variation support. If you are preparing a global submission programme and want to understand how we can support it, get in touch.